Previous Close | 7.61 |
1-Year Change | 222.46% |
6-Months Change | -4.99% |
3-Months Change | 0.93% |
Moving Avg (50d) | 7.0212 |
Moving Avg (200d) | 7.6264 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 402.3M |
Beta (3-Years) | 1.28 |
Revenue Growth (ttm) | -91.59% |
Net Profit Margin (ttm) | -28124.01% |
Return On Assets (ttm) | -47.11% |
EPS (ttm) | -1.54 |
PE Ratio (ttm) | -4.94 |
Dividend Yield | % |
Asset Description: | Altimmune, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2024-11-26 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
9.027 | 9.293 | 9.47 | 9.735 | 10.178 | 10.62 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |